|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0027625,
umls-concept:C0030705,
umls-concept:C0069515,
umls-concept:C0205160,
umls-concept:C0229671,
umls-concept:C0242957,
umls-concept:C0278493,
umls-concept:C0441889,
umls-concept:C0449438,
umls-concept:C0677930,
umls-concept:C0680730,
umls-concept:C1148554
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-1-16
|
|
pubmed:abstractText |
At the time when metastatic disease is identified, assessment of human epidermal growth factor receptor (HER)2 status might help to optimize treatment decisions if HER2 status was not determined at first diagnosis and if HER2 positivity has been acquired during disease progression. Within this context, determination of serum HER2 or evaluation of HER2 status in circulating tumor cells (CTCs) may be of clinical relevance because metastatic tissue may be difficult to obtain for analysis as a result of its localization. The aim of this study was therefore to determine the HER2 status in serum and corresponding CTCs in patients with metastatic breast cancer whose primary tumors were HER2 negative or of unknown HER2 status.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-10327070,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-1090362,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-11406546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-11406641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-11555569,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-11555582,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-11919237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12142389,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12142395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12176781,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12243512,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12370762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12529347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12560435,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12810150,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-12966347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-14500583,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-15014012,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-15194824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-15218357,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-15258994,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-15317891,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-15739264,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-15987448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-16106267,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-16236737,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-16236738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-16777917,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-16857794,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-16894399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-16943567,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-17079488,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-17159189,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-17686164,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-2470152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-2999974,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-6095109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-7605658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-7908410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17963511-8694559
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1465-542X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
R74
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17963511-Adult,
pubmed-meshheading:17963511-Aged,
pubmed-meshheading:17963511-Bone Neoplasms,
pubmed-meshheading:17963511-Breast Neoplasms,
pubmed-meshheading:17963511-Female,
pubmed-meshheading:17963511-Gene Amplification,
pubmed-meshheading:17963511-Humans,
pubmed-meshheading:17963511-Middle Aged,
pubmed-meshheading:17963511-Neoplasm Recurrence, Local,
pubmed-meshheading:17963511-Neoplasm Staging,
pubmed-meshheading:17963511-Neoplastic Cells, Circulating,
pubmed-meshheading:17963511-Prognosis,
pubmed-meshheading:17963511-Receptor, erbB-2,
pubmed-meshheading:17963511-Receptors, Estrogen,
pubmed-meshheading:17963511-Receptors, Progesterone
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse, D-72076 Tuebingen, Germany. Tanja.fehm@t-online.de
|
|
pubmed:publicationType |
Journal Article
|
